Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04672434 · ClinicalTrials.gov registry record · Phase 1
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
A Phase 1 study, sponsored by Symphogen A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT04672434 is a Phase 1 study that has completed, run by Symphogen A/S. The registered enrollment target is 48 participants.
The verdict
NCT04672434, a Phase 1 study, has completed, sponsored by Symphogen A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.
Interventions
- DRUG Sym021
- DRUG Sym024
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-11-19 |
| Est. Completion | 2024-11-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04672434
The ClinicalTrials.gov registry entry for NCT04672434 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Symphogen A/S, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sym021 is the first listed.
NCT04672434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04672434 about?
NCT04672434 is a clinical study titled "Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies". The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.
What is the current status of trial NCT04672434?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2020-11-19. Estimated completion is 2024-11-22.
What interventions are being tested in trial NCT04672434?
The interventions under investigation include: Sym021 (DRUG), Sym024 (DRUG).
Who is sponsoring clinical trial NCT04672434?
This trial is sponsored by Symphogen A/S, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.